Figure 1.

Isavuconazole (ISA) is as effective as a high dose of LAmB in treating murine mucormycosis due to M. circinelloides f. jenssenii. (a) Serum ISA concentration in mice (n = 6 mice per group) treated with different doses of the antifungal agent given three times daily for 4 days. Sera were collected 4 h after the last dose. (b) Survival of neutropenic mice (n = 10 per group except LAmB-treated mice, which had 9 mice) infected intratracheally with M. circinelloides f. jenssenii (instilled inoculum of 1.7 × 10³ per mouse) and treated with ISA (given orally) at 110 mg/kg ‘three times daily’ (ISA 110), ISA at 215 mg/kg three times daily (ISA 215) or LAmB (given iv) at 15 mg/kg once daily. *P < 0.005 versus placebo-treated mice. (c) Lungs and brain fungal burden of mice (n = 9 for placebo- or ISA-treated mice and 10 for LAmB-treated mice) infected with M. circinelloides f. jenssenii, treated on day +1 through day +4 and sacrificed on day +7, relative to infection. Data are expressed as median ± IQR. *P < 0.02 versus placebo-treated mice, **P < 0.05 versus placebo and ISA-treated mice and ^‡P < 0.0001 versus placebo-treated mice.